18 Oct 2021

Jnetics Launches New Expanded Testing Panel

From Early October, Jnetics, the only UK charity dedicated to the management and prevention of
genetic disorders prevalent in the mainstream Jewish community, will increase its testing panel from
nine to 47 conditions.

 
Nicole Gordon CEO explained, “This is a hugely exciting development in the history of Jnetics. The
panel has been increased to include further conditions prevalent in the Ashkenazi community, and
for the first time we will include conditions prevalent in the Sephardi and Mizrahi communities. We
are now encouraging any young Jewish adults with at least one Jewish grandparent to come forward
and be tested”.
 
“The additional conditions have been carefully selected based on a number of inclusion criteria and
under the guidance of Jnetics Scientific and Medical advisory committee. While these disorders vary
in severity, they are all life-threatening, debilitating and life-shortening” Alegria Vaz Mouyal
Research and Development Manager further explained, All these disorders are recessive conditions,
meaning there is only a 1 in 4 chance of having an affected child if both parents carry the faulty
gene. Carriers of the faulty gene are NOT affected.
 
The test itself is a simple spit test, which since the onset of Covid-19, is carried out virtually via 5
simple steps. Jnetics works in conjunction with the NHS, ensuring that if a couple are both found to
be carriers of the same genetic conditions, they can be streamlined into the NHS system.
 
Jnetics currently tests, Year 12 students in all 9 Jewish secondary schools across the country, Jewish
students at any UK university and through the Jnetics’ clinic, young couples thinking about starting a
family. For further information on where and how to get tested please visit
www.jnetics.org/screening.
 
“Currently, so many health issues are beyond our control. Screening for Jewish Genetic Disorders
and managing the risk of having a child with one of the severe life threatening and or life shortening
genetic disorders that we screen for is not” – Nicole Gordon , CEO concluded.
 
For further information on Jnetics visit www.jnetics.org or email Alegria on guila@jnetics.org